Puerarin for OVX-Induced Postmenopausal Osteoporosis in Murine Model: Systematic Review and Meta-Analysis

Author(s): Xiaobin Yang, Haishi Zheng, Yuan Liu, Dingjun Hao, Baorong He*, Lingbo Kong*

Journal Name: Current Stem Cell Research & Therapy

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Aims/Background: Ovariectomy (OVX)-induced murine model is widely used for postmenopausal osteoporosis study. Our current study was conducted to systematically review and essentially quantified the bone mass enhancing effect of puerarin on treating OVX-induced postmenopausal osteoporosis in murine model.

Methods: Literatures from PUBMED, EMBASE, and CNKI were involved in our searching strategy by limited the inception date to January 9th, 2019. Moreover, the enhancing effect of puerarin on bone mass compared to OVX-induced rats is evaluated by four independent reviewers. Finally, all the data were extracted, quantified and analyzed via RevMan, besides that in our current review study, we assessed the methodological quality for each involved study.

Results: Based on the searching strategy, eight randomization studies were finally included in current meta-analysis and systematic review. According to the data analysis by RevMan, puerarin could improve bone mineral density (BMD); (eight studies, n=203; weighted mean difference, 0.05; 95% CI, 0.03-0.07; P<0.0001) using a random-effects model. There is no significant difference between puerarin and estrogen (seven studies, n=184; weighted mean difference, 0.00; 95% CI, -0.01 to 0.00; P=0.30).

Conclusion: Puerarin showed upregulating effects on bone mass in OVX-induced postmenopausal osteoporosis in murine model. More studies of the effect of puerarin on bone density in OVX animals are needed.

Keywords: Puerarin, ovariectomy, postmenopausal osteoporosis, meta-analysis, murine model, hypercalcemia.

[1]
Goyal L, Goyal T, Gupta ND. Osteoporosis and periodontitis in postmenopausal women: A systematic review. J Midlife Health 2017; 8(4): 151-8.
[http://dx.doi.org/10.4103/jmh.JMH_55_17] [PMID: 29307975]
[2]
Watts NB. Postmenopausal osteoporosis: A clinical review. J Womens Health (Larchmt) 2018; 27(9): 1093-6.
[http://dx.doi.org/10.1089/jwh.2017.6706] [PMID: 29583083 ]
[3]
Thulkar J, Singh S, Sharma S, Thulkar T. Preventable risk factors for osteoporosis in postmenopausal women: Systematic review and meta-analysis. J Midlife Health 2016; 7(3): 108-13.
[http://dx.doi.org/10.4103/0976-7800.191013] [PMID: 27721637]
[4]
Deeks ED. Denosumab: A review in postmenopausal osteoporosis. Drugs Aging 2018; 35(2): 163-73.
[http://dx.doi.org/10.1007/s40266-018-0525-7] [PMID: 29435849]
[5]
Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. Abaloparatide is an effective treatment option for postmenopausal osteoporosis: Review of the number needed to treat compared with teriparatide. Calcif Tissue Int 2018; 103(5): 540-5.
[http://dx.doi.org/10.1007/s00223-018-0450-0] [PMID: 29951742]
[6]
Lin J, Zhu J, Wang Y, et al. Chinese single herbs and active ingredients for postmenopausal osteoporosis: From preclinical evidence to action mechanism. Biosci Trends 2017; 11(5): 496-506.
[http://dx.doi.org/10.5582/bst.2017.01216] [PMID: 29151553]
[7]
Sun H, Yin M, Qian W, Yin H. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Med Sci Monit 2018; 24: 6178-86.
[http://dx.doi.org/10.12659/MSM.910201] [PMID: 30182951]
[8]
Hirose A, Terauchi M, Akiyoshi M, Owa Y, Kato K, Kubota T. Low-dose isoflavone aglycone alleviates psychological symptoms of menopause in Japanese women: A randomized, double-blind, placebo-controlled study. Arch Gynecol Obstet 2016; 293(3): 609-15.
[http://dx.doi.org/10.1007/s00404-015-3849-0] [PMID: 26294070]
[9]
Li X, Sun S, Tong E. Experimental study on the protective effect of puerarin to Parkinson disease. J Huazhong Univ Sci Technolog Med Sci 2003; 23(2): 148-50.
[http://dx.doi.org/10.1007/BF02859940] [PMID: 12973933]
[10]
An J, Yang H, Zhang Q, et al. Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci 2016; 147: 46-58.
[http://dx.doi.org/10.1016/j.lfs.2016.01.024] [PMID: 26796578]
[11]
Ok HM, Gebreamanuel MR, Oh SA, Jeon H, Lee WJ, Kwon O. A Root-based combination supplement containing Pueraria lobata and Rehmannia glutinosa and exercise preserve bone mass in ovariectomized rats fed a high-fat dieT. Calcif Tissue Int 2015; 97(6): 624-33.
[http://dx.doi.org/10.1007/s00223-015-0057-7] [PMID: 26319677]
[12]
Hai Li, Jinhua Wang, Hailin Huang: Effects of purerain on OVXinduced osteoporosis. Zhong guo gu zhu zhi yu kang fu 2011; 46: 8698-701.
[13]
Li J, Zhang C. Effects of purerain on OVX-induced rat's serum. Chang zhi yi xue 2009; 1: 13-5.
[14]
Huang Y, Shi F. Effects of purerain on OVX-induced osteoporotic index in rat. Zhongguo Linchuang Kangfu 2004; 12: 2307-9.
[15]
Tong Huang, Bangquan Jin, Guiju Sun, Xianfeng Du, Xiao: Improved effects of purerain on OVX-induced rats.Xian dai yu fang yi xue 2010; 20: 3894-6.
[16]
Li H, Wang J, Huang H, Chen J, Therapeutic effects of purerain on OVX-induced osteoporosis. Zhong guo lao nian xue za zhi 2012; 18: 3950-52.
[17]
ao Liu, Binbin Li: The preserve effetcs of purarein on estrogen lacked osteoporosis.Zhong guo bi jiao yi xue 2012; 6: 16-20.
[18]
Hailing Huang, Hai Li, Jinhua Wang: Optimal dosage of purerain on OVX-induced osteoporosis in rat. Zhong Guo Zhu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu 2011; 33: 6111-4.
[19]
Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6): 785-95.
[http://dx.doi.org/10.1001/jama.285.6.785] [PMID: 11176917]
[20]
Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006; 194(2)(Suppl.): S12-23.
[http://dx.doi.org/10.1016/j.ajog.2005.08.049] [PMID: 16448872]
[21]
Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U. Bone mass and the risk of breast cancer: The influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 2007; 56(3): 312-21.
[http://dx.doi.org/10.1016/j.maturitas.2006.09.005] [PMID: 17049767]
[22]
Roux S, Massicotte MH, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. Bone 2019; 120: 482-6.
[http://dx.doi.org/10.1016/j.bone.2018.12.012] [PMID: 30572144]
[23]
Zeng X, Zhang Y, Wang S, et al. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca2+-NFATc1 signaling pathway and prevents ovariectomy-induced bone loss. Biochem Pharmacol 2017; 124: 57-68.
[http://dx.doi.org/10.1016/j.bcp.2016.10.007] [PMID: 27789216]
[24]
Tsubaki M, Satou T, Itoh T, et al. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 2012; 361(1-2): 219-31.
[http://dx.doi.org/10.1016/j.mce.2012.05.002] [PMID: 22579611]
[25]
Kong L, Zhao Q, Wang X, Zhu J, Hao D, Yang C. Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells. BMC Complement Altern Med 2014; 14: 481.
[http://dx.doi.org/10.1186/1472-6882-14-481] [PMID: 25496242]
[26]
Kong L, Ma R, Yang X, et al. Psoralidin suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines. Int Immunopharmacol 2017; 51: 31-9.
[http://dx.doi.org/10.1016/j.intimp.2017.07.003] [PMID: 28779592]
[27]
Kong L, Yang C, Yu L, et al. Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice. PLoS One 2013; 8(4)e61013
[http://dx.doi.org/10.1371/journal.pone.0061013] [PMID: 23613773]
[28]
Chen L, Liu C, Rui F, Zhu G. 1H, 15N and 13C chemical shift assignments of the SH2 domain of human tensin2 (TENC1). Biomol NMR Assign 2011; 5(2): 211-4.
[http://dx.doi.org/10.1007/s12104-011-9302-9] [PMID: 21461930]
[29]
Yang X, Gao W, Wang B, et al. Picroside II inhibits RANKL-mediated osteoclastogenesis by attenuating the NF-κB and MAPKs signaling pathway in vitro and prevents bone loss in lipopolysaccharide treatment mice. J Cell Biochem 2017; 118(12): 4479-86.
[http://dx.doi.org/10.1002/jcb.26105] [PMID: 28464271]
[30]
Xue Y, Jiang L, Cheng Q, et al. Adipokines in psoriatic arthritis patients: The correlations with osteoclast precursors and bone erosions. PLoS One 2012; 7(10)e46740
[http://dx.doi.org/10.1371/journal.pone.0046740] [PMID: 23144698]
[31]
Yuan SY, Sheng T, Liu LQ, et al. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro. Chin J Nat Med 2016; 14(4): 265-9.
[http://dx.doi.org/10.1016/S1875-5364(16)30026-7] [PMID: 27114313]
[32]
Zhang Z, Ren H, Shen G, et al. Animal models for glucocorticoid-induced postmenopausal osteoporosis: An updated review. Biomed Pharmacother 2016; 84: 438-46.
[http://dx.doi.org/10.1016/j.biopha.2016.09.045] [PMID: 27685786]
[33]
Lee SK, Kim H, Park J, et al. Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts. Sci Rep 2017; 7(1): 17332.
[http://dx.doi.org/10.1038/s41598-017-17427-6] [PMID: 29230013]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [37 - 42]
Pages: 6
DOI: 10.2174/1574888X14666190703143946
Price: $65

Article Metrics

PDF: 17
HTML: 4